01—Abstract
Summary
Summary of the 8-K filed July 31, 2025. Cited figures are marked; the original filing is the authoritative source.
Biogen reported second-quarter 2025 results on July 31, 2025, with total revenue of $2.65 billiona, up 7% year over year (8% at constant currency).
GAAP diluted EPS was $4.33b (up 8%) and Non-GAAP diluted EPS was $5.47 (up 4%). Results were helped by launch products: LEQEMBI U.S. in-market sales of about $63 million (up 20% sequentially), SKYCLARYS global revenue of about $130 million, and ZURZUVAE revenue of $46 million (up 68% sequentially). Revenue was also lifted by contract manufacturing and Alzheimer's collaboration revenue, and the U.S. MS business was resilient, aided by roughly $75 million of favorable gross-to-net and inventory timing.
Core multiple sclerosis product revenue still declined 4%, and Biogen flagged expected ex-U.S. MS competition in the second half, particularly for TECFIDERA in Europe. Management raised full-year 2025 guidance. Non-GAAP diluted EPS is now $15.50 to $16.00c, up from $14.50 to $15.50, which reflects a $0.87 benefit from the stronger outlook partly offset by about $0.12 from the City Therapeutics transaction.
Total revenue is now expected to be roughly flat at constant currency versus 2024, improved from a mid-single-digit decline. Biogen also expects minimal contract manufacturing revenue in Q4 2025 due to planned plant maintenance. The Fit for Growth program is expected to yield about $800 milliond net savings by year-end 2025, and combined Non-GAAP R&D and SG&A is expected at about $4.0 billion.
Balance sheet and cash flow were weaker in the quarter. Operating cash flow was about $161 million, held down by roughly $745 million of cash tax payments, yielding free cash flow of about $134 million. Biogen ended the quarter with about $2.8 billion of cash against $6.3 billion of debt, for net debt of about $3.5 billion, up from the prior year as notes payable rose from $4.5 billion to $6.3 billion.
Pipeline progress included salanersen moving to registrational studies in SMA and initiation of three Phase 3 felzartamab studies in kidney disease. Biogen also plans a September 3, 2025 investor event focused on its late-stage lupus assets.
02—Key points
Key Highlights
- Q2 2025 total revenue of $2,646 million, up 7% year over year (8% at constant currency), with GAAP diluted EPS of $4.33 and Non-GAAP diluted EPS of $5.47.
- Full-year 2025 Non-GAAP diluted EPS guidance raised to $15.50 to $16.00 from $14.50 to $15.50; total revenue now expected roughly flat at constant currency versus 2024, up from a mid-single-digit decline.
- LEQEMBI U.S. in-market sales of about $63 million (up 20% sequentially); global in-market sales of about $160 million, including a one-time China shipment of about $35 million.
- SKYCLARYS global revenue of about $130 million (U.S. about $78 million, up 13% sequentially); ZURZUVAE revenue of $46 million, up 68% sequentially.
- Core MS product revenue declined 4% to $1,107 million, while Q2 benefited from roughly $75 million of favorable gross-to-net and inventory timing in the U.S.; ex-U.S. TECFIDERA competition is expected to intensify in H2 2025.
- Free cash flow was only about $134 million in Q2 due to roughly $745 million of cash tax payments; net debt rose to about $3.5 billion as notes payable increased to $6.3 billion.
- Pipeline advances include salanersen moving to registrational stage in SMA, initiation of three Phase 3 felzartamab studies in kidney disease, and a September 3, 2025 investor event on late-stage lupus assets.
03—Questions
Frequently Asked Questions
Why did Biogen raise its full-year 2025 EPS guidance?
Biogen raised Non-GAAP diluted EPS guidance to $15.50 to $16.00 from $14.50 to $15.50. The company cited a $0.87 benefit from a stronger expected business outlook, partly offset by roughly $0.12 from the City Therapeutics transaction. Revenue guidance also improved to roughly flat at constant currency versus 2024.
Is Biogen's growth now driven by new products or by the core MS franchise?
Growth is coming mainly from launch products and non-core lines. Launch products such as LEQEMBI, SKYCLARYS and ZURZUVAE grew strongly, and contract manufacturing and Alzheimer's collaboration revenue rose sharply. Core MS product revenue fell 4%, and Q2 MS results were helped by about $75 million of one-time-like timing benefits, so the core franchise is still under pressure.
Why was free cash flow weak in the second quarter?
Operating cash flow of about $161 million absorbed roughly $745 million of cash tax payments. After $27 million of capital expenditures, free cash flow was about $134 million, compared with $592 million a year earlier. Management did not frame the tax payments as recurring, but the quarter shows how lumpy cash generation can be.
How leveraged is Biogen after its recent debt activity?
At June 30, 2025, Biogen had about $2.8 billion of cash and $6.3 billion of total debt, giving net debt of about $3.5 billion. Notes payable rose from $4.5 billion at year-end 2024 to $6.3 billion, while the current portion of notes payable went to zero, which indicates refinancing or reclassification of maturing debt.
What should investors watch in the second half of 2025?
Key items include ex-U.S. MS competition, especially TECFIDERA in Europe; minimal contract manufacturing revenue in Q4 2025 because of planned plant maintenance; whether LEQEMBI and SKYCLARYS sustain growth; progress on the salanersen SMA and felzartamab Phase 3 programs; and the September 3, 2025 lupus-focused investor event. Guidance excludes unannounced acquisitions, litigation, and tax or healthcare reform.
04—Continue